指南与共识呼吸道感染

韩国成人肺炎球菌疫苗接种:2025年韩国感染病学会推荐

Pneumococcal Vaccination in Korean Adults: 2025 Recommendations by the Korean Society of Infectious Diseases
RSS 订阅 · 指南共识 · 肺炎 · 2025-09-17

韩国于2024年10月批准20价肺炎球菌结合疫苗(PCV20)。鉴于老年及高危成人中侵袭性肺炎球菌病和肺炎球菌社区获得性肺炎负担仍高,且非PCV13血清型感染增加,韩国感染病学会基于近期临床试验的免疫原性、安全性和成本效果数据,推荐65岁及以上成人及19-64岁高危成人接种单剂PCV20,或序贯接种15价肺炎球菌结合疫苗后接23价肺炎球菌多糖疫苗(PPSV23)。疫苗选择、接种间隔和程序应根据个体基础疾病和既往接种史确定。

要点

  • 65岁及以上成人及19-64岁高危成人推荐单剂PCV20或PCV15序贯PPSV23。
  • 血清型3和19A仍是最流行血清型,非PCV13血清型感染增加。
  • 疫苗选择、剂量间隔和程序应基于个体基础疾病和既往接种史。

核心结论

  • 韩国感染病学会推荐65岁及以上成人及19-64岁高危成人接种单剂PCV20或PCV15序贯PPSV23,以扩大血清型覆盖并简化接种策略。

研究设计与样本

  • 韩国感染病学会基于近期临床试验的免疫原性、安全性和成本效果数据制定推荐。

主要发现

  • 韩国2024年10月批准PCV20。
  • 尽管已有国家免疫规划包含儿童肺炎球菌结合疫苗和成人PPSV23,老年及高危成人中侵袭性肺炎球菌病和肺炎球菌社区获得性肺炎负担仍高。
  • 血清型3和19A(均包含于PCV13)仍是最流行血清型,非PCV13血清型感染增加。

关键数值与推荐

  • 推荐65岁及以上成人及19-64岁高危成人接种单剂PCV20,或序贯接种PCV15后接PPSV23。
  • 疫苗选择、剂量间隔和程序应根据个体基础疾病和既往接种史确定。

临床怎么用

  • 对65岁及以上成人及19-64岁高危成人,可选用单剂PCV20或PCV15序贯PPSV23方案。
  • 接种决策需结合个体基础疾病和既往肺炎球菌疫苗接种史个体化制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infect Chemother. 2025 Sep;57(3):335-339. doi: 10.3947/ic.2025.0042. Epub 2025 Sep 4. ABSTRACT The 20-valent pneumococcal conjugate vaccine (PCV20) was approved by the Korean Ministry of Food and Drug Safety in October 2024. Despite the ongoing national immunization programs that include pneumococcal conjugate vaccines for children and 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults, the burden of invasive pneumococcal disease and pneumococcal community-acquired pneumonia remains high among the elderly and high-risk adults. Serotypes 3 and 19A, both included in 13-valent pneumococcal conjugate vaccine (PCV13), continue to be the most prevalent serotypes, and infections caused by non-PCV13 serotypes have increased. Given the need to broaden serotype coverage and simplify vaccination strategies, the Korean Society of Infectious Diseases recommends either a single dose of PCV20 or sequential vaccination with 15-valent pneumococcal conjugate vaccine followed by PPSV23 for adults aged 65 years and older, and for high-risk adults aged 19-64 years. These recommendations are based on immunogenicity, safety, and cost-effectiveness data from recent clinical trials. Vaccine selection, dosing intervals, and schedules should be determined according to individual underlying medical conditions and previous vaccination history to optimize protection against pneumococcal disease in the adult population. PMID: 40958490 | PMC: PMC12511744 | DOI: 10.3947/ic.2025.0042

来源:指南共识 · 肺炎,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 肺炎:Pneumococcal Vaccination in Korean Adults: 2025 Recommendations by the Korean Society of Infectious Diseases

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。